Clinical Trial Update: Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy [Phase 1, Phase 2]

View source ↗

Summary

The document reports completion of Phase 1 and Phase 2 evaluation of 123I-Iodometomidate for adrenal scintigraphy. It focuses on adrenal tumors and adrenocortic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Tumor
• Adrenocortical Carcinoma

Drugs mentioned

• 123I-Iodometomidate (Iodometomidate labeled with iodine-123)

Snippet

Sponsor: University of Wuerzburg | Conditions: Adrenal Tumor, Adrenocortical Carcinoma | Phase 1, Phase 2 | Status: COMPLETED